Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-708 in healthy subjects
NCT05347394Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-708 in acute pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Adverse Events and Columbia Suicide Severity Rating Scale. Started Apr 2022; status: completed.
02
Drugs
VX-708
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05347394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347394.